A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer
Despite treatment advances, breast cancer remains a leading cause of death of women in the United States, mostly due to metastatic disease. Bone is a preferential site for breast cancer metastasis, and most metastatic breast cancer patients experience bone involvement at the time of death. The major...
Main Authors: | Elizabeth Magno, Karen M. Bussard |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/25/6/3407 |
Similar Items
-
Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy
by: Zhifeng Jia, et al.
Published: (2023-01-01) -
Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers
by: Huanrong Lan, et al.
Published: (2024-01-01) -
MicroRNAs: Emerging Regulators of Metastatic Bone Disease in Breast Cancer
by: Marie-Therese Haider, et al.
Published: (2022-01-01) -
Megakaryocytes in Bone Metastasis: Protection or Progression?
by: Paola Maroni
Published: (2019-02-01) -
Osteocytes and Bone Metastasis
by: Manuel A. Riquelme, et al.
Published: (2020-10-01)